Kinnevik

Kinnevik is a leading growth investor, active owner, and operational partner that provides patient capital to challenger technology-enabled businesses in Europe and the US. They focus on passionate founders building tomorrow’s leaders within healthcare, software, and climate, aiming to make everyday life easier and better for people around the world. Kinnevik invests at all stages of a company’s growth journey, with a determined focus on creating long-term value. They actively participate in the governance structures of their investee companies, including monitoring risk management and compliance. Kinnevik's investment strategy emphasizes identifying companies with the potential to redefine industries. This includes backing companies with strong visions and robust technologies, such as Solugen, which aims to decarbonize the chemicals industry. They look for opportunities to increase supply chain resilience and drive efficiency through innovative solutions and domestic manufacturing. Kinnevik also targets corporate travel transformation through platforms like Perk, which offers transparency and control over travel expenses while enhancing the user experience. In the healthcare sector, Kinnevik focuses on companies like Oviva, which provide digital health solutions. They invest in businesses that leverage AI and big data to transform biotech, such as Solugen's use of AI-designed enzymes. Their climate strategy involves supporting companies that meaningfully reduce global CO2 emissions. They actively engage with their investments, as demonstrated by their participation in industry conferences and partnerships, such as Solugen's partnership with American Rheinmetall Munitions.

Healthcare, Software, Climate

Thematische Schwerpunkte und Zielmarktsegmente von Interesse.